New Report on Lung Cancer Therapeutic Antibodies Published by MarketPublishers.com

07 Oct 2011 • by Natalie Aster
New Report on Lung Cancer Therapeutic Antibodies Published by MarketPublishers.com

LONDON – Treatment of cancer, and, in particularly, lung cancer (which is the most common), is a double-edged sword: it should be as aggressive as possible to completely destroy the tumour, but it is precisely this aggressiveness which often causes severe side effects — a reason why some promising therapeutics can not be applied systemically. In addition, therapeutics such as cytokines that physiologically function in a para- or autocrine fashion require a locally enhanced level to exert their effect appropriately. An elegant way to accumulate therapeutic agents at the tumour site is their conjugation/fusion to tumour-specific antibodies.

New research report “Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical” worked out by Biopharm Reports presents a detailed and all-encompassing coverage of 27 candidate therapeutic antibodies, directed at 17 potential targets, that are being evaluated for the treatment of lung cancer. The review incorporates R&D and clinical developments in the treatment of lung cancer as the primary indication, as well as studies that are evaluating lung cancer alongside other cancers. Technical and market insights and perspectives in the development and clinical evaluation of therapeutic antibodies for the treatment of lung cancer, competitive and market-related information can also be found in the research work.

Report Details:

Title: Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical
Published: October, 2011
Pages: 135
Price: US$ 1,200.00

Reports Contents:

EXECUTIVE SUMMARY

CHAPTER 1 BACKGROUND
Summary
1 Lung Cancer
1.1 Statistics
1.2 Diagnosis
1.3 Lung Cancer Staging
1.4 Treatment of Lung Cancer
1.5 Survival Rates
1.6 Cost of Lung Cancer
1.7 New Developments
1.8 This Report
References

CHAPTER 2 APPROVED AND LATE-STAGE THERAPEUTIC ANTIBODIES
Summary
2.1 Introduction
2.2 Overview
2.3 (One antibody, Approved)
2.4 – 2.6 (Three antibodies, Phase 3)
References

CHAPTER 3 EARLY-STAGE THERAPEUTIC ANTIBODIES
Summary
3.1 Introduction
3.2 Overview
3.3 – 4.12 (Ten antibodies, Phase 2)
3.13 – 4.18 (Six antibodies, Phase 1/2)
3.19 – 4.23 (Five antibodies, Phase 1)
4.24 – 4.25 (Two antibodies, Preclinical)
References

CHAPTER 4 OTHER CANDIDATE THERAPIES
Summary
4.1 Introduction
4.2 Overview
4.3 (One Immune Activator, Phase 2)
4.4 (One Antibody Conjugate, Phase 1/2)
4.5 (One Bispecific Antibody, Phase 1)
4.6 (One Antibody Conjugate, Phase 1)

To order the report or ask for free sample pages, please contact ps@marketpublishers.com

 

CONTACTS

The Market Publishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970

ps@marketpublishers.com

www.marketpublishers.com